8 Article(s)Download |
PMID | Title | Pub. Year | #Total Relationships |
1 | 34856074 | Pathway profiling of a novel SRC inhibitor, AZD0424, in combination with MEK inhibitors for cancer treatment. | 2022 Mar | 1 |
2 | 31804471 | Heterogeneity and dynamics of active Kras-induced dysplastic lineages from mouse corpus stomach. | 2019 Dec 5 | 1 |
3 | 29348467 | Efficacy of MEK inhibition in a K-Ras-driven cholangiocarcinoma preclinical model. | 2018 Jan 18 | 1 |
4 | 29945997 | Assessing Therapeutic Efficacy of MEK Inhibition in a KRASG12C-Driven Mouse Model of Lung Cancer. | 2018 Oct 1 | 1 |
5 | 30021885 | PP2A inhibition is a druggable MEK inhibitor resistance mechanism in KRAS-mutant lung cancer cells. | 2018 Jul 18 | 1 |
6 | 28938614 | Phenformin enhances the therapeutic effect of selumetinib in KRAS-mutant non-small cell lung cancer irrespective of LKB1 status. | 2017 Aug 29 | 2 |
7 | 25541062 | AZD6244 inhibits cisplatin-induced ERK1/2 activation and potentiates cisplatin-associated cytotoxicity in K-ras G12D preclinical models. | 2015 Mar 1 | 2 |
8 | 22425996 | A murine lung cancer co-clinical trial identifies genetic modifiers of therapeutic response. | 2012 Mar 18 | 3 |